MSTN and hepatocellular carcinoma: Considering that patients with high serum myostatin levels at the baseline had higher risks of HCC, hepatic decompensation, and liver-related death than those with low myostatin levels, myostatin might be more involved with fibrotic progression than carcinogenesis in the liver.